when were glp 1 agonists approved for weight loss Weight-loss drugs such as Ozempic in the headlines a lot in 2025 – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Frontiers | GLP−1 receptor agonists

But what if there was a sugar

The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease

Daily GLP-1 support supplement formulated to complement weight loss medications

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma

Some sub-analyses of large clinical trials suggest that GLP-1RA and sodium-glucose cotransporter 2 inhibitor combination therapy may provide more significant reductions in heart failure hospitalization and renal composite events than each alone

Low-income Californians who use Wegovy and similar medications for weight loss lost their coverage at the start of the new year, with officials advising diet and exercise instead